Abstract
Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Reviews on Recent Clinical Trials
Title: Dendritic Cell Immunotherapy for Melanoma
Volume: 1 Issue: 2
Author(s): Judy C. Peng, Ranjeny Thomas and Keith Dredge
Affiliation:
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Abstract: Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Export Options
About this article
Cite this article as:
Peng C. Judy, Thomas Ranjeny and Dredge Keith, Dendritic Cell Immunotherapy for Melanoma, Reviews on Recent Clinical Trials 2006; 1 (2) . https://dx.doi.org/10.2174/157488706776876517
DOI https://dx.doi.org/10.2174/157488706776876517 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Prediction of Activities of BRAF (V600E) Inhibitors by SW-MLR and GA-MLR Methods
Current Computer-Aided Drug Design CD147 Promotes Melanoma Progression Through Hypoxia-Induced MMP2 Activation
Current Molecular Medicine Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Pattern of Care for Skin Cancers - Canada and France
Current Cancer Therapy Reviews Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Editorial [Hot topic: Focal Adhesion Kinase Signaling in Cancer- Part II (Guest Editor: Vita M. Golubovskaya)]
Anti-Cancer Agents in Medicinal Chemistry Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design Anal Carcinoma
Current Cancer Therapy Reviews Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Surfactant Protein A - From Genes to Human Lung Diseases
Current Medicinal Chemistry Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry